10-Q quarterly report · filed Nov 5, 2026

Cryoport, Inc. (CYRX) Q3 2026 10-Q Quarterly Report

Short answer

Cryoport, Inc. (CYRX) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $50M (up 13.5% year over year) with net income of −$11M.

Q3 2026 key financials · XBRL

Revenue
$50M
+13.5% YoY · +2.6% QoQ
Net income
−$11M
−233.5% YoY · −31.5% QoQ
Operating margin
-17.5%
Gross margin
47.5%
EPS (diluted)
−$0.26
−160.0% YoY · −30.0% QoQ

Source: XBRL data from the Cryoport, Inc. (CYRX) Q3 2026 10-Q on SEC EDGAR. USD.

Cryoport, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Q3 revenue $50.2M, up 13.5% YoY from $44.2M
  • Gross margin 47.5% vs 48.2% YoY, Life Sciences Products margin 43.6% vs 46.4%
  • Best segment: Life Sciences Services revenue $28.6M, up 17.8%; BioStorage/BioServices up 25.1%
  • Operating cash flow $10.1M, versus $(9.5)M YoY; capital expenditures and equipment purchases $24.3M
  • Near-term outlook: operating losses expected amid expansion and technology investment; $186.2M notes repayment due December 2026

Risk Factors

  • No material changes to risk factors from the 2025 Annual Report
  • Carried-forward risk: unidentified or currently immaterial factors could adversely affect operations
  • Business risk: existing annual-report risks could materially impair financial condition and results
  • Regulatory risk: annual-report risks remain applicable, with no new quarterly developments disclosed

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Cryoport, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.